Findings

What do systematic reviews say?

4 questions · 4 findings · 4 reviews · Childhood Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 75%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 25%Moderate 0 · 0%High 0 · 0%

Dinutuximab‐containing immunotherapy vs usual care

Progression‐free survival ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma treated… 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Retinoic acid post‐consolidation therapy vs no further treatment

Progression‐free survival ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT

The review found no eligible studies for this question.

1 finding from 1 review

Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous haematopoietic… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rapid COJEC vs standard induction therapies

Progression‐free survival ‐ not reported · patients with high‐risk neuroblastoma

The review found no eligible studies for this question.

1 finding from 1 review

Rapid COJEC versus standard induction therapies for high‐risk neuroblastoma 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dexrazoxane vs no cardioprotective intervention or placebo

Progression‐free survival · adults with cancer receiving anthracyclines

Dexrazoxane may leads to lower progression‐free survival Defined as time from first date of… compared with no cardioprotective intervention or placebo (low certainty).

1 finding from 1 review

Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines 2022 · Cochrane Headline outcomes only
HR 0.62 [0.43, 0.9]
1 study · 164 participants
Low